UGT1A1 genotype as an indicator of neutropenia for FOLFOXIRI with bevacizumab in patients with mCRC (QUATTRO study)

被引：0
|
作者：
Oki, Eiji [1 ]
Yoshino, Takayuki [2 ]
Muro, Kei [3 ]
Emi, Yasunori [4 ]
Tsuji, Akihito [5 ]
Yamasaki, Kentaro [10 ]
Yamanaka, Takeharu [7 ]
Sakisaka, Hideki [6 ]
Kato, Takeshi [8 ]
Kanazawa, Akiyoshi [9 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan
[5] Kagawa Univ, Takamatsu, Kagawa, Japan
[6] Osaka Minato Cent Hosp, Osaka, Japan
[7] Yokohama City Univ, Yokohama, Kanagawa, Japan
[8] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[9] Kitano Hosp, Osaka, Japan
[10] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY-17-2
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of UGT1A1 Genotype on Risk of Coronary Artery Disease
    Korpi-Steiner, N. L.
    Baudhuin, L. M.
    Berger, P. B.
    Somers, V. K.
    Bryant, S. C.
    McConnell, J. P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 569 - 570
  • [32] UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
    Matthew P. Goetz
    Heidi A. McKean
    Joel M. Reid
    Sumithra J. Mandrekar
    Angelina D. Tan
    Mary A. Kuffel
    Stephanie L. Safgren
    Renee M. McGovern
    Richard M. Goldberg
    Axel A. Grothey
    Robert McWilliams
    Charles Erlichman
    Matthew M. Ames
    Investigational New Drugs, 2013, 31 : 1559 - 1567
  • [33] A UGT1A1 genotype-directed phase I study of irinotecan (CPT-11) combined with fixed dose of capecitabine in patients with metastatic colorectal cancer (mCRC)
    Kim, T.
    Sym, S.
    Lee, S.
    Ryu, M.
    Lee, J.
    Chang, H.
    Kim, H.
    Shin, J.
    Kang, Y.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC
    Bando, Hideaki
    Kotani, Daisuke
    Satake, Hironaga
    Hamaguchi, Tetsuya
    Shiozawa, Manabu
    Kotaka, Masahito
    Masuishi, Toshiki
    Yasui, Hisateru
    Kagawa, Yoshinori
    Komatsu, Yoshito
    Oki, Eiji
    Yamamoto, Yoshiyuki
    Kawakami, Hisato
    Misumi, Toshihiro
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Muro, Kei
    Yoshino, Takayuki
    Kato, Takeshi
    Tsuji, Akihito
    MED, 2024, 5 (09):
  • [35] UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
    Goetz, Matthew P.
    McKean, Heidi A.
    Reid, Joel M.
    Mandrekar, Sumithra J.
    Tan, Angelina D.
    Kuffel, Mary A.
    Safgren, Stephanie L.
    McGovern, Renee M.
    Goldberg, Richard M.
    Grothey, Axel A.
    McWilliams, Robert
    Erlichman, Charles
    Ames, Matthew M.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1559 - 1567
  • [36] Cost-effectiveness study of UGT1A1 genotype screening in patients who require irinotecan for a colorectal cancer
    Pichereau, S.
    Le Louarn, A.
    Lecomte, T.
    Blasco, H.
    Le Guellec, C.
    Bourgoin-Herard, H.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 102 - 102
  • [37] Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
    Innocenti, Federico
    Schilsky, Richard L.
    Ramirez, Jacqueline
    Janisch, Linda
    Undevia, Samir
    House, Larry K.
    Das, Soma
    Wu, Kehua
    Turcich, Michelle
    Marsh, Robert
    Karrison, Theodore
    Maitland, Michael L.
    Salgia, Ravi
    Ratain, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) : 2328 - 2334
  • [38] Cost-effectiveness study of UGT1A1 genotype screening in patients who require irinotecan for a colorectal cancer
    Pichereau, S.
    Le Louarn, A.
    Lecomte, T.
    Blasco, H.
    Le Guellec, C.
    Bourgoin, H.
    PHARMACY WORLD & SCIENCE, 2008, 30 (06): : 1023 - 1023
  • [39] Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
    Vivaldi, C.
    Arrigoni, E.
    Morganti, R.
    Pecora, I.
    Fidilio, L.
    Catanese, S.
    Restante, G.
    Fornaro, L.
    Crucitta, S.
    Lencioni, M.
    Rofi, E.
    Vasile, E.
    Falcone, A.
    Danesi, R.
    Del Re, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?
    Hoskins, J. M.
    Goldberg, R. M.
    McLeod, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345